Artificial Intelligence Enters the Fray: Will AI Streamline Prior Authorization in Healthcare or Exacerbate Patient Denials?
The intersection of advanced technology and healthcare administration is currently experiencing a significant shift as the government pilots a program leveraging artificial intelligence for insurance-coverage decisions. This initiative, spearheaded by the Centers for Medicare and Medicaid Services (CMS) under the current administration, aims to reduce unnecessary medical spending and enhance efficiency in the often-cumbersome prior authorization process. However, this deployment of AI, particularly through the Wasteful and Inappropriate Service Reduction (WISeR) Model, is met with considerable skepticism and concern from physicians, patient advocates, and even lawmakers who fear it could exacerbate existing challenges, leading to increased denials and delayed access to medically necessary care. The debate centers on whether AI can truly alleviate the administrative burden and improve patient outcomes, or if its implementation risks creating a more opaque and profit-driven system that prioritizes cost savings over patient well-being.
The Prior Authorization Conundrum: A System Under Scrutiny
For many Americans, navigating the healthcare system involves a frustrating hurdle known as prior authorization. This process requires patients or their physicians to obtain approval from their health insurer before certain medical treatments, prescription medications, or procedures can be covered. While theoretically designed to prevent overuse, ensure medical necessity, and curb escalating healthcare costs by guiding patients toward less expensive or equally effective alternatives, prior authorization has become a significant source of contention and administrative burden.
Patients frequently recount harrowing experiences of prolonged delays, bureaucratic complexities, and outright denials for physician-recommended care. Personal stories abound in media outlets and patient forums illustrating the tribulations faced by individuals trying to secure coverage for essential services, often leading to significant emotional distress and, in some cases, adverse health outcomes. Physicians, too, are vocal in their criticism. A large majority of medical professionals consistently report that prior authorization procedures contribute to care delays, forcing patients to abandon recommended treatments while awaiting insurer verification of eligibility and medical necessity. The American Medical Association (AMA) has been a leading voice in highlighting these concerns, noting that such delays can have serious consequences for patient health. For instance, a 2025 AMA survey revealed that 94% of physicians reported care delays due to prior authorization, and 80% stated that the process can lead to patients abandoning treatment altogether. Furthermore, appealing a denial, while an option, adds further layers of time and complexity to an already arduous process.
The sheer volume of prior authorization requests underscores the systemic scale of the issue. In Medicare Advantage plans alone – the privately run alternative to original Medicare that now covers approximately 55% of Medicare-eligible seniors and disabled individuals – insurers issue millions of full or partial claim denials annually based on prior authorization criteria. Federal reports from the HHS Office of Inspector General (OIG) have consistently raised red flags, documenting instances where Medicare Advantage organizations denied beneficiaries access to services even when those services met coverage rules. For example, a 2022 OIG memorandum highlighted that more than one in ten denials by Medicare Advantage plans were for services that appeared to meet Medicare coverage rules. While many of these denials are eventually overturned on appeal (Medicare Advantage plans overturned 81% of denials upon appeal in 2024), the initial denial and the subsequent appeals process create significant obstacles to timely care.
The Promise and Peril of Artificial Intelligence in Prior Authorization
In this complex landscape, artificial intelligence emerges as a potential solution. Proponents argue that AI’s ability to rapidly process and analyze vast datasets could revolutionize prior authorization by efficiently sifting through medical records, clinical guidelines, and policy documents. This could theoretically expedite the approval of unambiguously allowable claims, thereby significantly reducing the delays that plague the current system. The vision is one where routine approvals are automated, freeing up human staff to focus on more complex cases requiring nuanced clinical judgment. Such automation could also standardize decision-making, potentially reducing human error and inconsistencies across different reviewers.
However, the introduction of AI into such a critical, patient-facing process is not without its challenges and strong resistance. Critics contend that while AI holds the promise of efficiency, it also carries the inherent risk of increasing wrongful denials of health insurance coverage. The very algorithms designed to streamline decisions could, if not carefully developed and monitored, introduce biases or rigidly apply rules without considering individual patient circumstances. The 2025 American Medical Association survey of physicians underscored this concern, with a significant 61% of doctors expressing worry that AI would exacerbate denials of what they deem medically necessary treatments. This fear stems from the perception that AI, without robust human oversight and transparency, could become an impersonal gatekeeper, further distancing patients from the care they need. The black-box nature of some AI models also raises concerns about accountability and the ability to challenge decisions effectively.
Health policy analyst Camm Epstein succinctly articulated this sentiment in an email to Undark, stating, "AI should be used to make appropriate care easier to approve, not necessary care easier to deny." This statement encapsulates the core ethical dilemma facing the integration of AI into prior authorization: will it serve as a tool for patient access or primarily as a mechanism for cost containment that could inadvertently harm patients?
The WISeR Model: A Federal Pilot Initiative and its Chronology
Responding to ongoing pressures to reduce healthcare waste and fraud, the current administration launched a significant demonstration project this year (2026) called WISeR, or Wasteful and Inappropriate Service Reduction Model. This ambitious initiative, which is set to run through December 2031, is being piloted in six states under the purview of the Centers for Medicare and Medicaid Services (CMS). Its primary objective is to leverage AI to decrease unnecessary procedures and identify potential areas of fraud and abuse within original Medicare, a sector where prior authorization has historically been less prevalent compared to Medicare Advantage.
The WISeR model integrates advanced technologies, particularly machine learning, with human clinical review. The AI components are tasked with evaluating services that CMS identifies as potentially vulnerable to overuse, fraud, and abuse. Examples of such services include skin and tissue substitutes, electrical nerve stimulator implants, and knee arthroscopy for knee osteoarthritis. The intent is for the AI to flag suspicious or non-compliant requests, which are then subject to human review by clinical experts. CMS asserts that by integrating AI into the prior authorization process, the WISeR model will "ensure timely and appropriate Medicare payment for select items and services."
However, this expansion of prior authorization, particularly with an AI component, into original Medicare marks a significant shift and has been met with considerable apprehension. While prior authorization has been extensively used in Medicare Advantage, its limited deployment in original Medicare has been a point of distinction, often viewed as offering beneficiaries more direct access to care. Critics worry that introducing this mechanism, especially one driven by AI, could erode this advantage for original Medicare beneficiaries. The states chosen for the pilot program include diverse healthcare landscapes, aiming to gather comprehensive data on the model’s effectiveness and impact across different populations and provider networks.
Controversy, Criticism, and Early Findings from WISeR
The WISeR model has faced substantial political pushback and scrutiny even before its full implementation. Wendell Potter, a prominent advocate for health insurance reform and former Cigna executive, has extensively covered the political resistance against the model on the Substack publication "HEALTH CARE un-covered." Similarly, Zena Wolf, a researcher with the Center for Health & Democracy, cited investigations by leading news organizations like the Washington Post, KFF Health News, and the Seattle Times, which suggested that in its initial months of operation, the WISeR model has already caused care delays and denials in some instances across the six pilot states. These reports highlight the administrative burden it places on healthcare providers, who often face additional work dealing with AI-driven denials, despite the promise of automation. Providers must dedicate staff time to understanding new AI criteria, submitting additional documentation, and navigating appeal processes, which can offset any potential efficiency gains.
A particularly contentious aspect of the WISeR model is its financial structure. Vendors participating in the program, hired to carry out the AI-driven prior authorization, earn a share of what CMS refers to as "averted expenditures." This means these vendors potentially generate revenue by rejecting care requests, creating a direct financial incentive for denials. This profit-making model has raised long-standing concerns about whether the system is designed to discourage patients from receiving medically necessary care. Several lawmakers, echoing these anxieties, have introduced resolutions and amendments aimed at blocking funding for the WISeR model, citing grave threats to patient access and the potential for undue influence by profit-driven entities. These legislative efforts reflect a broader concern about the ethical implications of financial incentives that could compromise patient care decisions.
Patient Impact and Systemic Burdens
Beyond the WISeR model, the broader impact of prior authorization on patients remains a critical concern. A newly released Commonwealth Fund survey in June 2026 underscored the widespread public perception of prior authorization as a major burden. The survey found that approximately one in five American working-age adults with private insurance reported that they or a family member were denied insurance coverage for physician-recommended medical care in 2025. The consequences of these denials are significant: 41% of individuals who experienced a prior authorization denial reported that it delayed their care, and more than a quarter indicated that their health problem worsened as a result. These statistics paint a stark picture of a system that, while intended to be a safeguard, often creates serious impediments to timely and effective treatment.
Patients caught in "prior authorization purgatory," as described by NBC News, often run out of time or treatment options while navigating complicated and cumbersome appeal processes. This is particularly true for vulnerable populations or those with complex medical conditions where delays can have catastrophic consequences. The emotional and financial toll on patients and their families is immense, extending beyond the direct medical costs to include lost wages, increased stress, and a diminished quality of life. The administrative burden also disproportionately affects smaller practices and those serving underserved communities, who may lack the resources to navigate complex digital prior authorization systems or manage extensive appeals.
Government and Industry Responses: A Mixed Bag of Reforms
Recognizing the growing dissatisfaction and systemic issues, both government bodies and private insurers have initiated efforts to reform prior authorization protocols. In 2024, the former Biden administration issued a significant rule designed to streamline the process for patients with government-run plans and physicians. This rule mandated that insurers make certain prior authorization decisions within 72 hours for urgent requests and seven calendar days for non-urgent requests. These crucial timeline requirements officially went into effect on January 1, 2025, for most public sector health plans, representing a tangible step toward reducing delays.
In 2025, the current administration, alongside major insurers, also pledged to further streamline and accelerate prior authorization processes across the industry. Private insurance companies, in response, vowed to standardize electronic requests by 2027 and committed to reducing the volume of medical services subject to prior authorization by 2026, including common procedures like colonoscopies and cataract surgeries. These industry pledges, while welcomed, are viewed with a degree of caution, as their ultimate impact on denial rates and patient access remains to be fully seen. The American Hospital Association (AHA) and other provider groups have consistently called for more significant reductions and greater transparency in these commitments.
Indeed, the current administration appears to hold a somewhat contradictory stance on prior authorization. While expanding its use in original Medicare through AI with the WISeR model, it simultaneously exerts pressure on private insurers, including Medicare Advantage plans, to lessen and streamline their prior authorization requirements. A high-ranking official from the administration publicly warned insurance company executives to ease the burden themselves, or face federal regulation: "If you don’t do it yourselves, then we’re going to do it for you," the official reportedly stated, signaling a clear intent to intervene if voluntary reforms are insufficient.
In response to this governmental pressure, health plans recently released industry-based survey data suggesting compliance with administration demands. The survey indicated that between June 2025 and April 2026, requests for prior authorization declined by 11 percent. However, critical insight into whether the actual denial rate has decreased remains largely unknown, leaving stakeholders to question the true impact of these reported reductions. Critics, including KFF Health News, have pointed out the lack of granular data in such industry-reported statistics, making it difficult to assess genuine improvements in patient access.
The Broader Debate: Automation vs. Genuine Improvement
A further industry survey conducted last year offered a crucial assurance: all responding health plans agreed with the statement that "AI or algorithms without clinician or practitioner review are not used to deny prior authorization requests that involve medical necessity or clinical considerations." Furthermore, insurers promised increased transparency regarding the clinical reasoning underlying prior authorization decisions. While these assurances might alleviate some concerns about a complete lack of human oversight, placating the growing chorus of detractors will not be an easy task. The specifics of "clinician or practitioner review" and the level of human override capability remain key questions.
The core of the debate lies not just in the presence of AI, but in its application. Jared Dashevsky, a physician and founder of the media and educational platform Healthcare Huddle, articulated a common frustration: "AI could eliminate barriers, reduce administrative waste, give us more time with patients. But that’s not what’s being built." Instead, he warns of an "arms race to deny faster and appeal faster," suggesting that current implementations risk merely automating a broken system rather than fundamentally fixing it. This perspective highlights the fear that AI, if deployed without proper ethical safeguards and patient-centric objectives, could become a tool that amplifies existing systemic flaws rather than resolving them.
The implications extend beyond mere administrative efficiency to fundamental questions of healthcare ethics, patient autonomy, and the role of technology in medical decision-making. Ensuring algorithmic fairness, preventing discriminatory outcomes, and maintaining human accountability in AI-driven processes are paramount. Without clear regulatory frameworks, robust oversight, and a steadfast commitment to transparency, the integration of AI into prior authorization could erode patient trust and exacerbate inequities in access to care, particularly for vulnerable populations who may be disproportionately affected by algorithmic biases. The development of explainable AI (XAI) and rigorous validation of algorithms will be crucial for building trust and ensuring equitable outcomes.
Conclusion: A Crossroads for Healthcare and Technology
The journey to reform prior authorization, with or without AI, is at a critical juncture. The introduction of artificial intelligence, exemplified by models like WISeR, represents a bold, yet controversial, step towards modernizing healthcare administration. While the potential for AI to streamline processes, reduce waste, and enhance efficiency is undeniable, the current deployment raises serious concerns about patient access, the potential for increased denials, and the ethical implications of profit incentives tied to cost containment.
The coming years, leading up to the WISeR model’s conclusion in 2031 and beyond, will be crucial in determining whether AI truly serves as a transformative force for good in healthcare, or if it simply adds another layer of complexity and potential harm to an already beleaguered system. The outcome will depend not just on technological advancements, but on robust regulatory frameworks, unwavering commitment to transparency in AI algorithms, clear accountability mechanisms, and a steadfast focus on prioritizing patient well-being above all else. The ongoing dialogue among policymakers, healthcare providers, insurers, and patient advocates will be essential in shaping an AI-integrated prior authorization system that genuinely serves the interests of those it is intended to protect.
